Cargando…

Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid

PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuan, Lin, Yaqing, Chen, Huixin, Hu, Jianhua, Zhao, Hong, Yang, Meifang, Han, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505399/
https://www.ncbi.nlm.nih.gov/pubmed/37724093
http://dx.doi.org/10.2147/IDR.S425463
_version_ 1785106912429211648
author Zhang, Xuan
Lin, Yaqing
Chen, Huixin
Hu, Jianhua
Zhao, Hong
Yang, Meifang
Han, Dongsheng
author_facet Zhang, Xuan
Lin, Yaqing
Chen, Huixin
Hu, Jianhua
Zhao, Hong
Yang, Meifang
Han, Dongsheng
author_sort Zhang, Xuan
collection PubMed
description PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcus spp. in cerebrospinal fluid (CSF) samples. PATIENTS AND METHODS: From March 2021 to March 2023, 290 patients with suspected CNS infection were recruited from the First Affiliated Hospital, School of Medicine, Zhejiang University, and 74 patients were ultimately included in the study. Lastly, 22 patients with CNS cryptococcosis were included. Of these patients, 25 CSF samples were enrolled. The diagnostic performance of conventional assays [including India ink, cryptococcal antigen (CrAg) testing, and culture] and mNGS was evaluated for CNS cryptococcosis. RESULTS: In the 25 samples collected, the coincidence rates of mNGS with India ink, CrAg, and culture were 64.0% (16/25), 80.0% (20/25), and 80.0% (20/25), respectively. Without antifungal drug exposure, the coincidence rates were increased to 66.7% (10/15), 100.0% (15/15), and 93.3% (14/15), respectively. The coincidence rates after antifungal therapy were all decreased to 60.0% (6/10), 50.0% (5/10), and 60.0% (6/10), respectively. Moreover, in the 25 samples, the sensitivity of mNGS reached 80.0%, and of India ink, CrAg testing, and culture were 68.0, 100.0, and 60.0%, respectively. The mNGS showed an excellent positive rate (100.0%) in the 15 samples collected without antifungal drug exposure, which was significantly higher than the antifungal drug-exposed group (n = 10) (50.0%) (P = 0.005). The reads of Cryptococcus spp. before antifungal therapy were significantly higher than after it (median, 25,915 vs 2, P = 0.008). CONCLUSION: mNGS is an effective tool for diagnosing CNS cryptococcosis using CSF; however, its sensitivity decreases considerably in patients who have been effectively treated with antifungal drugs.
format Online
Article
Text
id pubmed-10505399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105053992023-09-18 Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid Zhang, Xuan Lin, Yaqing Chen, Huixin Hu, Jianhua Zhao, Hong Yang, Meifang Han, Dongsheng Infect Drug Resist Original Research PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcus spp. in cerebrospinal fluid (CSF) samples. PATIENTS AND METHODS: From March 2021 to March 2023, 290 patients with suspected CNS infection were recruited from the First Affiliated Hospital, School of Medicine, Zhejiang University, and 74 patients were ultimately included in the study. Lastly, 22 patients with CNS cryptococcosis were included. Of these patients, 25 CSF samples were enrolled. The diagnostic performance of conventional assays [including India ink, cryptococcal antigen (CrAg) testing, and culture] and mNGS was evaluated for CNS cryptococcosis. RESULTS: In the 25 samples collected, the coincidence rates of mNGS with India ink, CrAg, and culture were 64.0% (16/25), 80.0% (20/25), and 80.0% (20/25), respectively. Without antifungal drug exposure, the coincidence rates were increased to 66.7% (10/15), 100.0% (15/15), and 93.3% (14/15), respectively. The coincidence rates after antifungal therapy were all decreased to 60.0% (6/10), 50.0% (5/10), and 60.0% (6/10), respectively. Moreover, in the 25 samples, the sensitivity of mNGS reached 80.0%, and of India ink, CrAg testing, and culture were 68.0, 100.0, and 60.0%, respectively. The mNGS showed an excellent positive rate (100.0%) in the 15 samples collected without antifungal drug exposure, which was significantly higher than the antifungal drug-exposed group (n = 10) (50.0%) (P = 0.005). The reads of Cryptococcus spp. before antifungal therapy were significantly higher than after it (median, 25,915 vs 2, P = 0.008). CONCLUSION: mNGS is an effective tool for diagnosing CNS cryptococcosis using CSF; however, its sensitivity decreases considerably in patients who have been effectively treated with antifungal drugs. Dove 2023-09-13 /pmc/articles/PMC10505399/ /pubmed/37724093 http://dx.doi.org/10.2147/IDR.S425463 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Xuan
Lin, Yaqing
Chen, Huixin
Hu, Jianhua
Zhao, Hong
Yang, Meifang
Han, Dongsheng
Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title_full Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title_fullStr Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title_full_unstemmed Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title_short Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
title_sort diagnostic performance of metagenomic next-generation sequencing in central nervous system cryptococcosis using cerebrospinal fluid
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505399/
https://www.ncbi.nlm.nih.gov/pubmed/37724093
http://dx.doi.org/10.2147/IDR.S425463
work_keys_str_mv AT zhangxuan diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT linyaqing diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT chenhuixin diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT hujianhua diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT zhaohong diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT yangmeifang diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid
AT handongsheng diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid